A randomized clinical trial of histamine 2 receptor antagonism in treatment-resistant schizophrenia

Journal of Clinical Psychopharmacology

Volumn 33, Issue 4, 2013, Pages 472-478

  Meskanen, Katarina ^a   Ekelund, Heidi ^b   Laitinen, Jarmo ^c   Neuvonen, Pertti J ^a   Haukka, Jari ^a   Panula, Pertti ^d   Ekelund, Jesper ^a,e,f  

^a UNIVERSITY OF HELSINKI   (Finland)

^b Finnish Science Centre   (Finland)

^c HOSPITAL DISTRICT OF HELSINKI AND UUSIMAA   (Finland)

^d UNIVERSITY OF HELSINKI   (Finland)

^e VAASA HOSPITAL DISTRICT   (Finland)

^f NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

famotidine; histamine; schizophrenia

Indexed keywords

FAMOTIDINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; FOLLOW UP; HUMAN; OPEN STUDY; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; TREATMENT DURATION;

ADULT; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FAMOTIDINE; FEMALE; FINLAND; HISTAMINE H2 ANTAGONISTS; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; MONTE CARLO METHOD; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TIME FACTORS; TREATMENT OUTCOME;

EID: 84879844864     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3182970490     Document Type: Article

References (35)

1. Liberman RP, Kopelowicz A. Recovery from schizophrenia: a concept in search of research. Psychiatr Serv. 2005;56:735-742.
2. Carpenter WT Jr, Heinrichs DW, Wagman AM. Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry. 1988;145:578-583.
3. Seeman P, Schwarz J, Chen JF, et al. Psychosis pathways converge via D2 high dopamine receptors. Synapse. 2006;60:319-346.
4. Biedermann F, Fleischhacker WW. Emerging drugs for schizophrenia. Expert Opin Emerg Drugs. 2011;16:271-282.
5. Haas H, Panula P. The role of histamine and the tuberomamillary nucleus in the nervous system. Nat Rev Neurosci. 2003;4:121-130.
6. Hill SJ, Ganellin CR, Timmerman H, et al. International Union of Pharmacology. XIII. Classification of histamine receptors. Pharmacol Rev. 1997;49:253-278.
7. Iwabuchi K, Ito C, Tashiro M, et al. Histamine H1 receptors in schizophrenic patients measured by positron emission tomography. Eur Neuropsychopharmacol. 2005;15:185-191.
8. Prell GD, Green JP, Kaufmann CA, et al. Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptoms. Schizophr Res. 1995;14:93-104.
9. Nakai T, Kitamura N, Hashimoto T, et al. Decreased histamine H1 receptors in the frontal cortex of brains from patients with chronic schizophrenia. Biol Psychiatry. 1991;30:349-356.
10. Schwartz JC, Morisset S, Rouleau A, et al. Application of genomics to drug design: the example of the histamine H3 receptor. Eur Neuropsychopharmacol. 2001;11:441-448.
11. Toyota H, Dugovic C, Koehl M, et al. Behavioral characterization of mice lacking histamine H3 receptors. Mol Pharmacol. 2002;62:389-397.
12. Pillot C, Heron A, Schwartz JC, et al. Ciproxifan, a histamine H3-receptor antagonist/inverse agonist, modulates the effects of methamphetamine on neuropeptide mRNA expression in rat striatum. Eur J Neurosci. 2003;17:307-314.
13. Kaminsky R, Moriarty TM, Bodine J, et al. Effect of famotidine on deficit symptoms of schizophrenia. Lancet. 1990;335:1351-1352.
14. Whiteford HA, Stedman TJ, McGrath JJ, et al. An open-label study of famotidine as a treatment for schizophrenia. J Psychiatry Neurosci. 1995;20:239.
15. Deutsch SI, Rosse RB, Kendrick KA, et al. Famotidine adjunctive pharmacotherapy for schizophrenia: preliminary data. Clin Neuropharmacol. 1993;16:518-524.
16. Rosse RB, Kendrick K, Fay-McCarthy M, et al. An open-label study of the therapeutic efficacy of high-dose famotidine adjuvant pharmacotherapy in schizophrenia: preliminary evidence for treatment efficacy. Clin Neuropharmacol. 1996;19:341-348.
17. Gajtkowski GA, Norris DB, Rising TJ, et al. Specific binding of 3H-tiotidine to histamine H2 receptors in guinea pig cerebral cortex. Nature. 1983;304:65-67.
18. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P). New York: New York State Psychiatric Institute; 2002
19. Endicott J, Nee J, Fleiss J, et al. Diagnostic criteria for schizophrenia: reliabilities and agreement between systems. Arch Gen Psychiatry. 1982;39:884-889.
20. Andreasen NC. Negative symptoms in schizophrenia: definition and reliability. Arch Gen Psychiatry. 1982;39:784-788.
21. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276.
22. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare; 1976.
23. Kagevi I, Thorhallsson E, Wählby L. CSF concentrations of famotidine. Br J Clin Pharmacol. 1987;24:849-850.
24. Nagata Y, Kusuhara H, Hirono S, et al. Carrier-mediated uptake of H2-receptor antagonists by the rat choroid plexus: involvement of rat organic anion transporter 3. Drug Metab Dispos. 2004;32:1040-1047.
25. Odeh M, Oliven A. Central nervous system reactions associated with famotidine: report of five cases. J Clin Gastroenterol. 1998;27:253-254.
26. Ikawa K, Shimatani T, Hayato S, et al. Pharmacokinetic and pharmacodynamic properties of lafutidine after postprandial oral administration in healthy subjects: comparison with famotidine. Biol Pharm Bull. 2007;30:1003-1006.
27. Barzaghi N, Gatti G, Crema F, et al. Impaired bioavailability of famotidine given concurrently with a potent antacid. J Clin Pharmacol. 1989;29:670-672.
28. Echizen H, Ishizaki T. Clinical pharmacokinetics of famotidine. Clin Pharmacokinet. 1991;21:178-194.
29. Prell GD, Rosse RB, Deutsch SI. Apparent absence of famotidine- antipsychotic drug interactions in patients with chronic schizophrenia. J Psychiatry Neurosci. 1996;21:61.
30. R: A Language and Environment for Statistical Computing [computer program]. Version 2.14.2. Vienna, Austria: R Foundation for Statistical Computing; 2012.
31. lme4: Linear Mixed-Effects Models Using S4 Classes [computer program]. Version 0.999375-39. Vienna, Austria: R Foundation for Statistical Computing; 2011.
32. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223.
33. Humbert-Claude M, Davenas E, Gbahou F, et al. Involvement of histamine receptors in the atypical antipsychotic profile of clozapine: a reassessment in vitro and in vivo. Psychopharmacology. 2012;220:225-241.
34. Jin CY, Panula P. The laminar histamine receptor system in human prefrontal cortex suggests multiple levels of histaminergic regulation. Neuroscience. 2005;132:137-149.
35. Lawrence NS, Ross TJ, Stein EA. Cognitive mechanisms of nicotine on visual attention. Neuron. 2002;36:539-548.